GLP-3
$110.00
99%+ Purity · 5 mg · lot PATX-GLP3-5MG-2601-002
A synthetic triple agonist peptide engaging GLP-1, GIP, and glucagon receptors, studied for metabolic regulation and body composition signaling in preclinical research.
Batch and certificate of analysis
Latest tested lot — 10 mg: DPS-4296192 · tested September 3, 2026 · Horizon Analytical. The results below are from the certificate for this exact lot, not a representative sample. This product ships in more than one strength; this card shows the most recently tested lot only. The certificate for each strength's own lot is on the COA page.
| Parameter | Result | Method | Specification |
|---|---|---|---|
| Identity | GLP-3 · Pass | UPLC/MS | Confirmed |
| Appearance | White lyophilized powder | Visual | Meets specification |
| Purity | 99.49% · Pass | UPLC/MS | Specification > 98% |
| Net content | 10.08 mg | UPLC/MS | Labeled 10 mg |
| Endotoxin | <0.05 EU/mL | Endotoxin test | Reported |
Certificates for every released lot of this product are on the COA page.
Research specifications
| Form | Lyophilised powder in a sealed glass vial |
| Labeled content | 10 mg |
| Appearance (current lot) | White lyophilized powder |
| Storage | Sealed vials cold, dry and protected from light; frozen for long-term storage |
| Intended use | Laboratory research only |
Identifiers
| Compound | GLP-3 |
| Molecular formula | C221H342N46O68 |
| Molecular weight | 4731 g/mol |
| CAS registry number | Not listed on the PubChem record |
| PubChem CID | 171390338 |
PubChem holds this peptide as depositor records rather than a single standardised compound; the CID above is the free-base depositor record. It lists no CAS registry number.
Identifiers are the values PubChem lists for the named record, checked September 2026. Where PubChem lists no CAS number, none is shown.
Identity, composition and analytical documentation
Each released lot is tested by an independent laboratory (Horizon Analytical for the current lot). The certificate reports identity by mass spectrometry, purity by UPLC/MS, and net content measured against the labeled amount. A separate endotoxin report accompanies the certificate for this lot. The certificate does not include heavy-metal, sterility, residual-solvent or microbial testing. The lot number on the certificate is the lot number on the vial, so a certificate can be matched to the material in hand. Certificates for every lot released on this site remain available on the COA page.
Research overview
Findings below are from the cited laboratory and animal studies; nothing here describes effects in people.
Research Overview
GLP-3 is a synthetic triple agonist peptide that engages three receptor systems: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. In vitro it shows balanced glucagon- and GLP-1-receptor activity with greater GIP-receptor activity (Coskun et al., Cell Metab 2022). This multi-receptor profile distinguishes it from single- and dual-agonist compounds.
Researchers investigate GLP-3 to understand how concurrent activation of incretin and glucagon signaling pathways influences energy homeostasis, lipid metabolism, and glucose regulation. The GLP-1 and GIP receptor pathways are studied for their roles in insulin secretion and appetite signaling; in obese mice, glucagon-receptor engagement added an increase in energy expenditure to the reduction in calorie intake driven by the two incretin receptors (Coskun et al. 2022) — a component that single- and dual-agonist peptides do not address.
Preclinical and early clinical trial data have generated significant interest in GLP-3's receptor binding kinetics, pharmacokinetic profile, and downstream signaling cascades. Its structure-activity relationship is studied alongside GLP-2 (dual agonist) and GLP-1 (single agonist) to characterize the incremental effects of adding each receptor target.
GLP-3 vs GLP-2: Triple vs Dual Agonist Research
The central research question distinguishing GLP-3 from GLP-2 is the contribution of glucagon receptor activation. Both compounds engage GLP-1 and GIP receptors, but GLP-3's additional glucagon receptor activity introduces thermogenic and lipolytic signaling dimensions absent in dual agonists. Preclinical comparisons examine whether this third receptor target produces additive metabolic effects — particularly in energy expenditure, hepatic lipid handling, and adipose tissue remodeling — or whether the incretin pathways alone account for the majority of observed metabolic changes. See our detailed GLP-3 vs GLP-2 comparison for full mechanistic analysis.
Laboratory applications include receptor binding assays, metabolic pathway profiling, and comparative studies against other GLP-1 class compounds. GLP-3 is also studied in the context of body composition research due to its multi-target mechanism. For a foundational overview, see our What Is GLP-3? guide.
Sources: Coskun T, et al. Cell Metab. 2022;34(9):1234–1247 (in vitro receptor activity and obese-mouse studies; PubMed 35985340). Urva S, et al. Lancet. 2022;400(10366):1869–1881 (a human phase 1b study; reported for context only, not as a research-model finding; PubMed 36354040).
Explore the PeptidesATX Research Library for additional peptide pharmacology guides and reference resources.
GLP-3 compared with GLP-2
Both are incretin-receptor research peptides sold on this site. Rows describe receptor class and documentation, not effects.
| GLP-3 | GLP-2 | |
|---|---|---|
| Receptor class | Triple agonist: GLP-1, GIP and glucagon receptors | Dual agonist: GLP-1 and GIP receptors |
| Development code in the literature | LY3437943 | LY3298176 |
| What distinguishes it | Adds glucagon-receptor activity to the dual-incretin set | Dual incretin activity without a glucagon-receptor component |
| Certificate of analysis | Single-compound identity, purity and net content per lot | Single-compound identity, purity and net content per lot |
Scientific references
- Urva S, et al. Lancet. 2022;400(10366):1869–1881. PubMed 36354040
- Jastreboff AM, et al. N Engl J Med. 2023;389(6):514–526. PubMed 37366315
- Rosenstock J, et al. Lancet. 2023;402(10401):529–544. PubMed 37385280
Related research guides
- GLP-3 research guide — triple-receptor mechanism and preclinical models
- GLP-3 vs GLP-2 — dual and triple receptor agonism compared
- Triple vs dual agonist peptides — the receptor classes explained
- Peptide half-life chart — reported plasma half-life
Frequently asked questions
- Which lot will I receive, and how do I check it?
- The lot shown on this page (DPS-4296192) is the one currently shipping; when a new lot is released, this page and the COA page update together. The lot number is printed on the vial label and matches the certificate.
- What does the certificate of analysis cover?
- Identity and purity by UPLC/MS from an independent laboratory (Horizon Analytical), measured net content against the labeled amount, and appearance, with a separate endotoxin report; both documents are linked above as PDFs. The certificate does not include heavy-metal, sterility, residual-solvent or microbial testing.
- What identifiers should match the certificate?
- The compound name, molecular formula and molecular weight in the compound information block are the values PubChem lists for this compound; the certificate reports identity by mass spectrometry against the same molecular weight.
- How should the vial be stored on receipt?
- Sealed lyophilised vials are kept cold, dry and away from light; long-term storage is frozen. The handling notes on this page and the storage guide give the laboratory practice in more detail.
- When does an order ship?
- Orders placed before the daily cutoff shown above ship the same business day from Austin, Texas, with tracking. Delivery estimates and the free-shipping threshold are shown in the order summary.